Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma.
Park SJ, Kannan A, Harris JP, Lacy C, Daniels GA, Lee SP, Lambrecht N, Hook N, Olshan P, Billings PR, Aleshin A, Gao L. Park SJ, et al. Among authors: lee sp. J Am Acad Dermatol. 2022 Nov;87(5):1209-1211. doi: 10.1016/j.jaad.2022.03.020. Epub 2022 Mar 19. J Am Acad Dermatol. 2022. PMID: 35318107 Free article. No abstract available.
Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Parikh NR, et al. Among authors: lee sp. BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5. BMC Cancer. 2019. PMID: 30935383 Free PMC article.
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. Nickols NG, et al. Among authors: lee sp. Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.02.008. Online ahead of print. Eur Urol. 2024. PMID: 38490853 No abstract available.
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
Tward J, Lenz L, Flake DD II,, Rajamani S, Yonover P, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Fabrizio M, Salzstein D, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen T. Tward J, et al. Among authors: lee sp. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):66-76. doi: 10.1016/j.ijrobp.2021.09.034. Epub 2021 Oct 3. Int J Radiat Oncol Biol Phys. 2022. PMID: 34610388 Free article.
A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy.
Tsai CS, Lai CH, Chang TC, Yen TC, Ng KK, Hsueh S, Lee SP, Hong JH. Tsai CS, et al. Among authors: lee sp. Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):477-84. doi: 10.1016/j.ijrobp.2009.02.020. Epub 2009 May 21. Int J Radiat Oncol Biol Phys. 2010. PMID: 19464824 Clinical Trial.
1,131 results